2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101605
    Prodipine hydrochloride 31314-39-3 99.84%
    Prodipine, a diphenyl-phosphonate derivative. The IC50s of Prodipine for purified and plasma Dipeptidyl peptidase IV (DPP IV) from the rabbit are 4.5 μM and 30 μM, respectively.
    Prodipine hydrochloride
  • HY-10163S
    Dabigatran-d4 1618637-32-3 98%
    Dabigatran-d4 is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-d4
  • HY-101704
    Y1 receptor antagonist 1 221697-09-2 99.69%
    Y1 receptor antagonist 1 (H 409-22 isomer) (Example 4) is a neuropeptide Y1 receptor antagonist. Y1 receptor antagonist 1 can be used for the study of cardiovascular diseases, such as vasoconstriction.
    Y1 receptor antagonist 1
  • HY-101723
    Modecainide 81329-71-7 99.36%
    Modecainide is a major metabolite of Encainide, which is an antiarrhythmic agent.
    Modecainide
  • HY-10268S
    Betrixaban-d6 2098655-51-5 99.02%
    Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor.
    Betrixaban-d6
  • HY-103059
    SOICR-IN-1 1479049-35-8 99.62%
    SOICR-IN-1 (compound 32) is a store-overload induced calcium release (SOICR) inhibitor with an IC50 value of 14.6 μM. SOICR-IN-1 can be used for the research of cardiac arrhythmias.
    SOICR-IN-1
  • HY-103067
    A1899 498577-46-1 99.72%
    A1899 is a potent and highly selective blocker of the K2P channel TASK-1. A1899 has IC50 values of 35.1 nM and 7 nM for TASK-1 channels expressed in oocytes and CHO cells, respectively. A1899 is also an IKur blocker that can be used for the research of cardiovascular diseases.
    A1899
  • HY-103410
    Carmoxirole hydrochloride 115092-85-8 ≥98.0%
    Carmoxirole hydrochloride (EMD 45609 hydrochloride) is a selective, peripherally acting dopamine D2 receptor agonist and exhibits antihypertensive activities in vivo.
    Carmoxirole hydrochloride
  • HY-103445
    SSR69071 344930-95-6 ≥98.0%
    SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury. SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases.
    SSR69071
  • HY-105090
    Lerisetron 143257-98-1 99.18%
    Lerisetron is a potent 5-HT3 antagonists and possess high-affinity binding for the 5-HT3 receptors with pKi value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats.
    Lerisetron
  • HY-105454
    Recainam 74738-24-2 98%
    Recainam (Wy-42362) is an orally active anti-arrhythmic agent with Class I electrophysiological properties. Recainam suppresses complex ventricular arrhythmias. Racainam exhibits a good pharmacokinetic character in Sprague Dawley rats.
    Recainam
  • HY-105559
    Viquidil 84-55-9 98%
    Viquidil (Quinotoxine), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil shows antithrombotic activity.
    Viquidil
  • HY-105872
    Trifenagrel 84203-09-8 99.35%
    Trifenagrel is an orally active platelet aggregation inhibitor that inhibits the inducing effects of arachidonic acid (AA) and collagen. The ED50s of trifenagrel for inhibiting AA- and collagen-induced platelet aggregation in guinea pigs were 1.4 mg/kg and 9.4 mg/kg, respectively.
    Trifenagrel
  • HY-105946
    Hidrosmin 115960-14-0
    Hidrosmin, a flavonoid, is derived from Diosmin (HY-N0178). hidrosmin exerts a beneficial effect against diabetic nephropathy (DN) by reducing inflammation, oxidative stress, and senescence pathways. Hidrosmin can be used for the research of venous insufficiency and diabetes mellitus.
    Hidrosmin
  • HY-106262
    Delcasertib 949100-39-4 98.21%
    Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).
    Delcasertib
  • HY-106275
    FX-06 88650-17-3 99.98%
    FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS).
    FX-06
  • HY-106303
    YT 146 90596-75-1 99.72%
    YT 146 is a potent agonist of A2 adenosine receptor (A2 AR) agonist. YT 146 causes a concentreation dependent cAMP accumulation, with the EC50 of 1.5 nM. YT 146 has cardioprotective effects.
    YT 146
  • HY-106720
    Amosulalol 85320-68-9 98.69%
    Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR).
    Amosulalol
  • HY-106844
    EMD 53998 120223-04-3 99.59%
    EMD 53998 is a cardiotonic agent that increases myocardial contractility as an inhibitor for phosphodiesterase III (PDE III) and a calcium sensitizer. EMD 53998 increases myocardial contractility, reduces energy consumption and the risk of inducing arrhythmias.
    EMD 53998
  • HY-106994
    Nebentan 403604-85-3 99.67%
    Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo.
    Nebentan
Cat. No. Product Name / Synonyms Application Reactivity